Abstract:Homeodomain transcription factor A9 (HOXA9) is a member of the HOX cluster family of transcription factors that are crucially involved in embryo implantation, morphogenesis, body axis development, and endothelial cell differentiation. Despite numerous reports on its aberrant expression in a few malignancies, the molecular and functional complexity of HOXA9 across cancers remains obscure. We aimed to analyze the dynamic role of HOXA9 across cancers by identifying, analyzing, and understanding its multiple modes of regulation and functional implications and identifying possible therapeutic avenues. We conducted a comprehensive analysis to determine the role of HOXA9 across cancers. This approach involved the integration of large-scale datasets from public repositories such as the Genomic Data Commons, specifically the Cancer Genome Atlas (GDC-TCGA), across 33 different cancer types. The multiple modes of HOXA9 regulation by genetic and epigenetic factors were determined using online tools, which comprised experimentally validated observations. Furthermore, downstream pathways were identified by predicting the targets of HOXA9 and by performing functional enrichment analysis. We also assessed the clinical significance of HOXA9 in terms of prognosis and stage stratification. This study evaluated the correlation between HOXA9 and tumor-infiltrating molecules and discussed its association with therapeutically approved antineoplastic drugs. HOXA9 was significantly upregulated in 9 tumors and downregulated in 2 cancers. The deregulation of HOXA9 is primarily attributed to epigenetic factors, including promoter DNA methylation and noncoding RNAs (ncRNAs). The HOXA9 transcription factor interacts with PBX/MEIS cofactors and regulates multiple genes involved in cancer-associated EMT, autophagy, the cell cycle, metabolic pathways, Wnt signaling, TGF-β signaling, the AMPK pathway, PI3K/AKT signaling, and NF-κB signaling, thereby establishing control over downstream mechanisms. Differential expression in various clinical stages across cancers was shown to have prognostic significance and to be correlated with tumor-infiltrating immune molecules. The assessment of the correlation of HOXA9 expression with approved antineoplastic drugs revealed that targeting HOXA9 could be the most reliable strategy for preventing cancer progression. HOXA9 is upregulated in the majority of malignancies and drives cancer progression by regulating multiple signaling mechanisms. Hence, HOXA9 could be a reliable diagnostic indicator and a potential therapeutic candidate for solid cancer types.

The clinical significance and correlative signaling pathways of paired box gene 9 in development and carcinogenesis

PAX9 in Cancer Development

Decreased Expression Of Bar Is Correlated With Poor Prognosis In Oral And Oropharyngeal Carcinoma

Abstract P50: PAX9 Activates Cell Death via Autophagic Degradation of EGFR in Oral squamous Cell Carcinoma

PAX9 Regulates Squamous Cell Differentiation and Carcinogenesis in the Oro‐oesophageal Epithelium

Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers

PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer

An overview of PAX1: Expression, function and regulation in development and diseases

PAX9 Overexpression in Lung Adenocarcinoma and Promotes Cancer Progression

The Function and Regulatory Network of Pax9 Gene in Palate Development.

Abstract 4471: Pax9 Regulates Squamous Cell Differentiation and Alcohol-Associated Carcinogenesis in the Oro-Esophageal Epithelium

An inclusive study of deleterious missense PAX9 variants using user-friendly tools reveals structural, functional alterations, as well as potential therapeutic targets.

Paired Box 5 is a Frequently Methylated Lung Cancer Tumour Suppressor Gene Interfering Β‐catenin Signalling and GADD45G Expression

Pathogenic mechanisms of tooth agenesis linked to paired domain mutations in human PAX9

Paired Box 5 Increases the Chemosensitivity of Esophageal Squamous Cell Cancer Cells by Promoting P53 Signaling Activity

Functional study of novel <i>PAX9</i> variants: The paired domain and non-syndromic oligodontia

Functional study of novel PAX9 variants: The paired domain and non-syndromic oligodontia

Isoform- and dose-sensitive feedback interactions between paired box 6 gene and δ-catenin in cell differentiation and death

Pan-cancer exploration of oncogenic and clinical impacts revealed that HOXA9 is a diagnostic indicator of tumorigenesis

Prognostic Value of PAX9 in Patients with Esophageal Squamous Cell Carcinoma and Its Prediction Value to Radiation Sensitivity

Identification and functional analysis of two novel PAX9 mutations.